Skip to the line map
Before the Needle

What Is Bone Marrow Aspirate Concentrate (BMAC), and What Does It Contain?

  • Updated November 14, 2026
  • Stop 5 of 6 on the Stem cell basics line

Bone marrow aspirate concentrate (BMAC) is liquid bone marrow, usually drawn from your own hip bone, that has been spun in a centrifuge to concentrate its cells. The result is a mixture: mostly blood-forming and blood cells, platelets and other marrow components, with only a small and variable fraction of mesenchymal stromal or stem-like cells. It is not a purified or standardized dose of mesenchymal stem cells, and the amount of each component varies from person to person and system to system.

What does BMAC stand for?

BMAC stands for bone marrow aspirate concentrate. You may also see BMC, short for bone marrow concentrate. They describe the same kind of product. A 2025 study of knee injection prices in the Chicago area, for example, uses “BMC” for bone marrow aspirate concentrate; its figures are discussed in how much stem cell therapy costs.

BMAC is different from culture-expanded mesenchymal stromal cells, which are grown in a laboratory over days or weeks to produce large numbers of a more uniform cell population. BMAC is prepared the same day, without growing cells, so its cell makeup reflects whatever was in the marrow that was drawn.

What kinds of cells and components can BMAC contain?

Component Present in BMAC? Note
Blood-forming (hematopoietic) stem and progenitor cells Expected, in variable amounts Part of normal marrow; often not measured in a given sample
White blood cells and other nucleated blood cells Yes, typically a large share Counted in "total nucleated cells"
Platelets Yes Concentrated along with cells
Mesenchymal stromal or stem-like cells May be present as a small and variable fraction Not isolated or purified; the amount varies and is often not measured
Red blood cells Reduced but often present Depends on the system
Plasma proteins and signaling molecules Yes Not standardized

What BMAC does not guarantee:

What people may assume What is actually established
A fixed number of mesenchymal stem cells per injection Cell numbers vary widely between people and preparations
That most cells in the syringe are stem cells Most nucleated cells are blood-lineage cells
That a higher total cell count means a better result Cell counts describe the sample, not proven clinical potency
That the device used means FDA approved the treatment Device clearance or classification concerns the equipment, not the effectiveness of the injection
Cartilage regeneration Not established in controlled human trials

How is marrow collected and concentrated?

At a high level, the process has three steps. A clinician numbs the skin and bone surface, often at the back of the pelvis (the posterior iliac crest), and uses a needle to draw liquid marrow into syringes. The aspirate is placed in a processing system, typically a centrifuge, which separates components by density. The concentrated layer containing nucleated cells and platelets is collected and injected, often the same day.

The procedure has its own risks: pain at the harvest site, bruising or bleeding, and infection or injury to nearby structures. Processing and handling outside the body add the risk of contamination if sterile technique fails. These risks are part of the decision, separate from whether the injection helps.

Why do BMAC products vary between patients and systems?

Several factors change what ends up in the syringe:

  • The person: marrow composition differs between individuals and can change with age and health.
  • The harvest site and technique: where the needle goes, how much is drawn from one spot, and how quickly.
  • The processing system: different devices concentrate cells differently.
  • How results are reported: studies count total nucleated cells, colony-forming units or specific markers, and those measures are not interchangeable.

A 2025 systematic review and meta-analysis of BMAC collection sites and cellular yield found large variability in measured yields. Its outcomes describe what was collected; they are not established measures of how well an injection will work.

What has BMAC been studied for, and what remains uncertain?

BMAC has been studied in orthopedic settings, most visibly knee osteoarthritis, and in cartilage and bone repair procedures. A 2025 clinical review of BMAC in knee osteoarthritis describes its composition and the limits of the evidence. Results from trials of laboratory-grown mesenchymal stromal cells cannot be transferred to BMAC, because they are different products.

Guideline bodies have not endorsed it for knee osteoarthritis. The <a href="https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/OA/Osteoarthritis-CPG2026-Guidelinefinal_20260618.pdf”>VA/DoD osteoarthritis guideline, Version 3.0 (May 2026) does not name BMAC; the closest category is bone marrow-derived stem cell injection in its Recommendation 22, which finds insufficient evidence to recommend for or against and is graded “Neither for nor against.” The VA/DoD 2026 patient companion, Orthobiologics at a Glance, says studies have not consistently shown meaningful improvements in pain or physical function with BMAC compared with standard treatments. Whether any cell-based injection rebuilds knee cartilage is reviewed in whether stem cell therapy can regrow knee cartilage.

On regulation: the centrifuges and kits used to make BMAC are medical devices. A device’s FDA classification or clearance concerns the equipment and its intended processing function. It is not FDA approval of a BMAC injection for joint pain, and it is not evidence that the injection works. FDA’s consumer alert on regenerative medicine lists orthopedic conditions among uses for which these products have not been approved.

Is BMAC the same as a stem cell injection? It is sometimes marketed that way, but it is a mixed concentrate in which mesenchymal stem-like cells are a small, variable minority.

Is a higher total cell count necessarily better? No. Total nucleated cell count mostly reflects blood-lineage cells, and it has not been established as a measure of clinical benefit.

Every stop on the Stem cell basics line

  1. Adult Stem Cells vs. Embryonic Stem Cells: How Are They Different?
  2. Are Mesenchymal Stem Cells and Mesenchymal Stromal Cells the Same Thing?
  3. Autologous vs. Allogeneic Stem Cells: What Does Each Term Mean?
  4. Bone Marrow vs. Fat-Derived Stem Cells: How Do the Sources Compare?
  5. What Is Bone Marrow Aspirate Concentrate (BMAC), and What Does It Contain?
  6. What Are Exosomes, and What Do They Do in the Body?

Reader comments

Leave a note on this stop

Your email address will not be published. Required fields are marked *